US Medical Early Asset Director – Market Access

US Medical Early AssetDirector Market Access

Are you ready to turn ideas into life-changing medicines At AstraZeneca we are committed to addressing the unmet needs of patients worldwide through scientific this role you will play a crucial role inleveragingour scientific capabilities to positively impact patients lives. Reporting directly to theHead of US Medical Early Asset Team Lead you willbe part of a teamfocused on the development of ambitious US medical strategies for our early pipeline. This is an opportunity to seize design and influence across a complex matrix system to ensure US needs are integrated into global development plans.

Accountabilities:
TheUS Medical Early Asset Manager Insightswill shape the US access strategy for pipeline assets from late discovery through Phase 2. You will translate emerging science into payer-relevant value inform clinical and evidence plans and ensure US access needs are embedded in global asset strategy. Partnering closely with Global/US Market Access HEOR Medical Clinical Development Commercial and Finance you will define early payer value propositions evidence requirements pricing and contracting hypotheses and policy risk mitigation to de-risk reimbursement at launch.

Key Responsibilities

• US Value Strategy and TPP Input: Define US payer-relevant elements of theTarget Product Profile(clinical endpoints comparators subpopulations line of therapy) and shape differentiation claims that resonate with payers and health systems.

• Evidence and Study Design Influence: Provide US access input to clinical and RWE plans (endpoints PROs inclusion/exclusion duration head-to-heads external controls) to support label compendia guideline inclusion and payer coverage.

• Payer Value Proposition & Dossier Foundations: Lead early value story development (unmet need clinical and economic value drivers) outline core claims and define requirements for future AMCP dossier modules and global value dossiers.

• Early Pricing and Contracting Hypotheses: Develop US WAC/NET ranges reference pricing considerations budget impact boundaries and contracting scenarios (e.g. outcomes-based indication-based) with assumptions and risks.

• HEOR & RWE Strategy: Co-create early economic models and RWE plans (burden of illness treatment patterns comparative effectiveness adherence/persistence) to support access and inform trial design.

• Access Policy and Channel Strategy: Assess policy landscape (Medicare Medicaid ACA IRA/Part D redesign 340B state policies) site-of-care and channel dynamics (buy-and-bill pharmacy benefit specialty distribution) and implications for design and launch.

• Payer IDN and PBM Insights: Plan and synthesize early payer/IDN advisory input and rapid tests (concept reviews value message testing coverage criteria simulations) to de-risk access hurdles.

• Competitive and Class Access Analytics:Maintainlandscape of class coverage criteria step/edit rulesutilizationmanagement coding/reimbursement precedents;identifyopportunities to differentiate andanticipatebarriers.

• Forecasting & Investment Support: Build access assumptions for early forecasts (gross-to-net access mix UM intensity speed-to-coverage) and partner with Finance onrNPV/scenario analyses for governance.

• Governance and Cross-Functional Leadership: Represent US access in global/US asset teams and at governance gates (indicationsequencing go/no-go TPP approval) driving clear evidence-backed recommendations.

• Compliance and Ethics:Operatewithin US promotional and pre-approval communication standards and company policies; ensure research and external interactions meet compliance requirements.

MinimumQualifications

• Education: Bachelors degree; advanced degree preferred (MPH MS HEOR PharmD MBA or related).

• 5years inpharmaceuticalor consultancy with a focus on US market access/HEOR; experienceinfluencing early development (Phase 12)stronglypreferred.

• Demonstrated impact shaping TPPs clinical design/evidence to meet payer needs and developing early value propositions and pricing/contracting hypotheses.

• Ability to translate clinical profiles into payer-relevant value andcoveragedrivers.

• Comfort interpreting economic models burden of illness and RWE methodologies; able to brief modeling teams and stress-test assumptions.

• Working knowledge of Medicare/Medicaid commercial payers PBMs 340B medical vs. pharmacy benefit dynamics coding/billing and site-of-care economics.

• Experience designing and synthesizing payer research advisory boards and message testing.

Preferred Qualifications

• Proven ability to lead without authority across Clinical Medical HEOR Commercial and Finance.

• Clear concise storyteller able to craft payer narratives and present to governance and senior stakeholders.

• Strong quantitative skills; scenario analysis and sensitivity testing to inform investment decisions.

• Operates in ambiguity manages multiple assets and meets fast-paced milestone timelines.

This position is based at our Wilmington DE campus headquarters for our US Biopharma we put unexpected teams in the same room we unleash bold thinking with the power to inspire life-changing -person working gives us the platform we need to connect work atpaceand challenge perceptions.Thatswhy we work on average a minimum of three days per week from the office. But thatdoesntmeanwerenot flexible. We balance the expectation of being in the office while respecting individual flexibility. Join us in our unique and ambitious world.

Next Steps Apply Today!

Are you ready to make a difference Apply now and join our mission to transform lives with our science!